RxDoctor Payments Data

Michaela Butler, PA

Physician Assistant · Chubbuck, IDNPI 1457927204

Payments from drug & device makers

$1,230in general payments, 2019–2025

Across 44 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$300
  • AbbVie$291
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$156
  • Teva Pharmaceuticals USA, Inc.$102
  • Neuronetics, Inc.$93
  • Alkermes, Inc.$82
  • plus $206 from 5 others

What the payments were for

  • Food & beverage$1,05085%
  • Education$18015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,230 in reported general payments places this provider in the 75th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$23,748
Medicare patients
48
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl45$59,562
Memantine Hcl17$1,490
Duloxetine Hcl69$1,420
Donepezil Hcl81$1,192
Olanzapine34$997
Bupropion XlBupropion Hcl51$815
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine25$803
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$646
Quetiapine Fumarate31$638
Buspirone Hcl30$578
Lorazepam43$481
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$330
Fluoxetine Hcl23$252
Propranolol Hcl ErPropranolol Hcl12$244
Hydroxyzine Hcl12$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$291$59,56245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Chubbuck

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →